"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B1,US 7428701 B1,006-955-208-592-763,2008-09-23,2008,US 21580498 A,1998-12-18,US 21580498 A,1998-12-18,"Method, system and computer program for redaction of material from documents","A method of redacting content from a document in electronic form includes the steps of selecting a geometric area on the document for redaction, representing the selected geometric area as one or more annotation objects, identifying information in the document representing content and location and nature of content, representing the identified information as one or more content objects, identifying content having the same geometric location as the annotation objects and creating a file with the identified content removed to produce a redacted document.",APPLIGENT INC,GAVIN MARK;;DUNN ROGER;;GAVIN VIRGINIA M,APPLIGENT INC (1999-03-01),https://lens.org/006-955-208-592-763,Granted Patent,yes,5,86,2,2,0,G06F40/169;;G06F40/169,G06F15/00;;G06F17/00,715/243;;715/246;;715/247;;715/788,6,1,081-845-973-581-01X,10.1145/248625.248652,"Gladney, H.M., Access control for large collections, ACM Transactions on Information Systems (TOIS), vol. 15, Issue 2, Apr. 1997, pp. 154-194.;;Precise/Discovery, Automating the entire litigation document collection process, Website <http://www.precise.ab.ca/products/discovery.html>, Precise Systems Corporation, Jul. 5, 1998 (confirmed via archive.org), downloaded on Dec. 4, 2002, pp. 1-3.;;Redax, Web article by Digital Applications, Inc., downloaded on Mar. 10, 2005, with a last update of Dec. 13, 1997, downloaded from <http://web.archive.org/web/19971221013620/http://digapp.com/>, pp. 1-2.;;Pontin, Jason, TechSmith ships Win95 screen capture utility, InfoWorld Jan. 15, 1996, vol. 18, Issue 3, pp. 1-3 (via ProQuest Direct).;;Microsoft Word 97-bundled with Microsoft Office 97, application screenshots, pp. 1-5, Microsoft Corporation, first released Oct. 1996.;;Microsoft newsgroup thread: Aug. 2001, newsgroup <http://groups.google.com/group/microsoft.public.word.newusers>, pp. 1-4.",EXPIRED
2,US,A1,US 2009/0070664 A1,103-618-178-106-275,2009-03-12,2009,US 19820308 A,2008-08-26,US 19820308 A;;US 21580498 A,1998-12-18,"METHOD, SYSTEM AND COMPUTER PROGRAM FOR REDACTION OF MATERIAL FROM DOCUMENTS","A method of redacting content from a document in electronic form includes the steps of selecting a geometric area on the document for redaction, representing the selected geometric area as one or more annotation objects, identifying information in the document representing content and location and nature of content, representing the identified information as one or more content objects, identifying content having the same geometric location as the annotation objects and creating a file with the identified content removed to produce a redacted document.",APPLIGENT INC,GAVIN MARK;;DUNN ROGER;;GAVIN VIRGINIA M,,https://lens.org/103-618-178-106-275,Patent Application,yes,5,40,2,2,0,G06F40/169;;G06F40/169,G06F17/00,715/234,0,0,,,,DISCONTINUED
3,US,B2,US 11667975 B2,049-034-672-022-434,2023-06-06,2023,US 201916393322 A,2019-04-24,US 201916393322 A;;US 201862662013 P,2018-04-24,Methods and systems for noninvasive and localized brain liquid biopsy using focused ultrasound,"Among the various aspects of the present disclosure is the provision of a noninvasive and localized brain liquid biopsy using focused ultrasound. Briefly, therefore, the present disclosure is directed to methods and systems to identify brain lesion or tumor characteristics without the need for a solid brain biopsy.",WASHINGTON UNIVERSITY ST LOUIS,LEUTHARDT ERIC;;DUNN GAVIN;;CHEN HONG;;PETTI ALLEGRA,WASHINGTON UNIVERSITY (2019-04-24),https://lens.org/049-034-672-022-434,Granted Patent,yes,10,0,3,4,6,A61B10/0045;;A61B2010/0077;;A61B2010/008;;C12Q1/6806;;C12N15/1003;;A61B5/0042;;A61B5/0036;;A61B5/702;;A61B2562/0204;;A61B5/6803;;A61B5/055;;C12Q1/6886;;A61B10/0045;;A61N7/00;;A61B5/055;;A61B5/0042;;A61B5/6803;;C12Q2600/156;;C12Q1/6851;;A61B2010/0077;;A61B2010/008;;A61N2007/006;;A61N2007/0078;;A61N2007/0039;;A61B90/11,A61B5/05;;A61B5/00;;A61B5/055;;A61B10/00;;A61B90/11;;A61N7/00;;C12Q1/6851;;C12Q1/6886,,70,67,080-552-757-796-272;;037-200-286-931-678;;003-005-058-047-381;;047-321-964-700-638;;020-574-020-858-249;;053-675-811-897-359;;084-920-540-312-400;;096-560-257-359-528;;041-766-872-619-385;;075-011-740-635-250;;003-848-900-055-507;;024-290-487-587-340;;063-853-780-692-650;;067-190-217-505-765;;002-246-238-942-739;;040-708-790-713-974;;081-413-070-506-407;;066-447-201-943-124;;036-495-506-050-384;;009-307-839-208-549;;027-574-743-905-007;;061-721-751-256-115;;048-341-126-148-340;;038-718-592-186-138;;013-079-411-490-734;;018-951-840-748-335;;053-294-657-664-442;;034-036-014-982-155;;059-380-929-828-199;;045-672-968-700-821;;059-042-176-882-657;;043-233-153-107-341;;102-661-138-846-428;;014-602-099-929-844;;032-906-433-632-225;;004-590-522-169-62X;;016-143-932-033-363;;030-211-409-957-800;;143-439-989-272-274;;111-952-381-373-700;;021-309-991-257-568;;023-275-201-889-027;;055-916-607-058-256;;061-410-597-143-180;;095-773-278-696-411;;005-932-362-637-757;;034-085-328-275-059;;140-724-655-991-715;;100-811-534-356-146;;073-182-667-529-964;;015-992-040-871-61X;;023-679-728-442-492;;087-744-301-235-574;;007-412-493-809-022;;029-948-399-540-526;;057-050-451-510-848;;087-882-852-586-35X;;106-113-857-334-830;;054-865-323-882-610;;043-045-573-329-428;;069-949-726-178-823;;064-980-553-392-71X;;057-857-452-163-830;;027-050-737-926-891;;100-449-965-589-436;;003-174-019-368-964;;021-391-323-430-906,10.1121/1.5035645;;pmc5565398;;28026755;;10.1109/tmi.2016.2643565;;24462453;;pmc4041837;;10.1016/j.addr.2014.01.008;;10.3171/2014.9.focus14521;;25434380;;28196593;;10.1016/j.ccell.2017.01.002;;pmc3968780;;20800172;;10.1016/j.ultrasmedbio.2010.06.005;;10.1007/s40120-017-0072-x;;28733961;;pmc5520818;;10.1126/scitranslmed.3007094;;24553385;;pmc4017867;;10.1136/bmj.322.7296.1222;;pmc1120332;;11358777;;23035067;;10.1212/wnl.0b013e31826e9b0a;;10.1021/cn300191b;;pmc3629738;;23379618;;10.1586/14737175.2015.1028369;;25936845;;pmc4702264;;21913188;;10.1002/ijc.26425;;pmc4083385;;10.1038/jcbfm.2014.71;;24780905;;25279463;;10.1371/journal.pone.0108880;;pmc4184840;;pmc5375625;;27802108;;10.1148/radiol.2016160024;;10.1063/1.3131471;;19846365;;pmc3968777;;10.1109/tbme.2009.2034533;;pmc3189054;;21930942;;10.1073/pnas.1105116108;;29348365;;10.1126/science.aar3247;;pmc6080308;;pmc5537489;;10.1038/bjc.2017.171;;28618431;;25945493;;pmc4422704;;10.1371/journal.pone.0125911;;10.1073/pnas.0903437106;;pmc2749842;;19805109;;10.1371/journal.pone.0194268;;pmc5856340;;29547636;;10.2217/fon.15.19;;25804124;;27662675;;10.1109/tuffc.2016.2609238;;28453784;;10.1093/neuonc/nox085;;pmc5737576;;17964019;;10.1016/j.ncl.2007.07.002;;23562017;;10.1016/j.ultrasmedbio.2012.12.015;;pmc1852449;;17210286;;10.1016/j.surneu.2006.07.014;;28674995;;10.1007/978-3-319-57193-5_20;;29896293;;pmc5996357;;10.7150/thno.24911;;10.1073/pnas.0604318103;;16868082;;pmc1544236;;28626862;;10.1002/mp.12412;;29988649;;pmc6027582;;10.1186/s40349-018-0113-7;;10.1007/s11060-011-0575-8;;21512826;;10.1016/j.wneu.2015.05.025;;26008141;;10.1002/ana.21801;;20033983;;pmc3533365;;10.1158/0008-5472.can-12-0128;;22552291;;10.5858/arpa.2018-0901-sa;;29504834;;pmc6457907;;30675060;;10.1038/s41586-019-0882-3;;10639039;;10.1097/00004424-200001000-00009;;10.1016/s0929-8266(97)00214-0;;pmc5381156;;27339763;;10.1016/j.ultrasmedbio.2016.05.004;;17052661;;10.1016/s1474-4422(06)70597-x;;10.1001/jama.2013.280319;;24193082;;22332065;;pmc3309801;;10.1148/radiol.11111417;;27793845;;10.1158/0008-5472.can-15-3231;;23823706;;10.1016/j.ultras.2013.05.014;;10.1007/s11060-015-1866-2;;26530259;;18546601;;10.1038/nprot.2008.73;;10.1179/175889709x446507;;20574549;;pmc2889676;;10.1126/science.358.6368.1341;;10.1016/j.trecan.2016.06.003;;pmc5461965;;28603776;;10.1159/000203122;;19372656;;pmc5715774;;10.1073/pnas.1713328114;;29133392;;10.1038/s41598-017-02217-x;;pmc5445070;;28546538;;26394701;;10.1586/14737159.2015.1087315;;25791797;;10.1016/j.drup.2015.02.002;;22411467;;10.1038/nrg3185;;pmc3654667;;10.1530/erc-15-0369;;pmc4737995;;26764421;;10.1038/nrneurol.2015.171;;26369507;;10.1016/j.ultrasmedbio.2014.11.019;;pmc4362523;;25728459;;27853267;;pmc5112571;;10.1038/srep37094;;10.1038/s41598-018-25904-9;;pmc5964111;;29789530;;25079538;;10.1038/511524a;;pmc6071656;;10.1093/neuonc/noy074;;29746665;;pmc5919906;;29700310;;10.1038/s41598-018-24516-7,"Aldiabat, H. et al. (Apr. 17, 2018), Wideband transskull refocusing of ultrasound beams using dual-mode ultrasound arrays: Ex vivo results, J. Acoust. Soc. Am., vol. 143, pp. 1731.;;Arvanitis, C. D. et al. (2016), Passive acoustic mapping with the angular spectrum method, IEEE Trans. Med. Imaging, vol. 36, No. 4, pp. 983-993.;;Aryal, M. et al. (2014), Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system, Adv. Drug Deliv. Rev., vol. 72, pp. 94-109.;;Aum, D. J. et al. (2014), Molecular and cellular heterogeneity: the hallmark of glioblastoma, Neurosurg., vol. 37, No. 6, pp. 1-11.;;Bardelli, A. et al. (2017), Liquid biopsies, what we do not know (yet), Cancer Cell, vol. 31, pp. 172-179.;;Baseri, B. et al. (2010), Multi-modality safety assessment of blood-brain barrier opening using focused ultrasound and definity microbubbles: a short-term study, Ultrasound Med. Biol., vol. 36, No. 9, pp. 1445-1459.;;Beach, T.G. (2017), A review of biomarkers for neurodegenerative disease: will they swing us across the valley?, Neurol. Ther., vol. 6, Supp 1, pp. S5-S13.;;Bettegowda C., et al. (2014), Detection of circulating tumor DNA in early- and late-stage human malignancies, Sci Transl Med, vol. 6, No. 224, pp. 224ra24.;;Blomley, M.J.K et al. (2001), “Science, medicine, and the future:Microbubble contrast agents: A new era in ultrasound”, BMJ, vol. 322, No. 7296, pp. 1222-1225.;;Boisselier, B. et al. (2012), Detection of IDH1 mutation in the plasma of patients with glioma, Neurology, vol. 79, No. 16, pp. 1693-1698.;;Burgess, A. et al. (2013), Noninvasive and targeted drug delivery to the brain using focused ultrasound, ACS Chem. Neurosci., vol. 4, No. 4, pp. 519-526.;;Burgess, A. et al. (2015), Focused ultrasound-mediated drug delivery through the blood-brain barrier, Expert Rev. Neurother., vol. 15, No. 5, pp. 477-491.;;Capper, D. et al. (2012), 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with 1DH1/2 mutation status or tumor size, Int. J. Cancer, vol. 131, pp. 766-768.;;Chen, H. et al. (2014), The size of blood-brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure, J. Cereb. Blood Flow Metab., vol. 34, pp. 1197-1204.;;Chen, H. et al. (2014), A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery, PLoS One, vol. 9, No. 10, pp. e108880.;;Chevillet, J. R. et al. (2016), Release of cell-free microRNA tumor biomarkers into the blood circulation with pulsed focused ultrasound: A noninvasive, anatomically localized, molecular liquid biopsy, Radiology, vol. 283, No. 1, pp. 158-167.;;Choi, J. J. et al. (2010), Microbubble-size dependence of focused ultrasound-induced blood-brain barrier opening in mice in vivo, IEEE Trans. Biomed. Eng., vol. 57, No. 1, pp. 145-154.;;Choi, J. J. et al. (2011), Noninvasive and localized neuronal delivery using short ultrasonic pulses and microbubbles, Proc. Natl. Acad. Sci. U. S. A, vol. 108, No. 40, pp. 16539-16544.;;Cohen, J. D. et al. (Feb. 2018), Detection and localization of surgically resectable cancers with a multi-analyte blood test, Science, vol. 359, No. 6378, pp. 926-930.;;Cyll, K. et al. (2017), Tumour heterogeneity poses a significant challenge to cancer biomarker research, BJC, vol. 117, pp. 367-375.;;Downs, M. E. et al. (2015), Long-term safety of repeated blood-brain barrier opening via focused ultrasound with microbubbles in non-human primates performing a cognitive task, PLoS One, vol. 10, No. 5, pp. e0125911.;;D'Souza, A. L. et al. (2009), A strategy for blood biomarker amplification and localization using ultrasound, Proc. Natl. Acad. Sci. U. S. A., vol. 106, No. 40, pp. 17152-17157.;;D'Souza, A. L. et al. (Mar. 2018), Tumor characterization by ultrasound-release of multiple protein and microRNA biomarkers, preclinical and clinical evidence, PLoS One, vol. 13, No. 3, pp. e0194268.;;El Kaffas, A. et al. (2015), Biomechanical effects of microbubbles: from radiosensitization to cell death, Future Oncol., vol. 11, No. 7, pp. 1093-1108.;;Ellens, N. et al. (2016), Pre-clinical MRI-guided focused ultrasound: A review of systems and current practices, IEEE Trans. Ultrason. Ferroelectr. Freq. Control, vol. 64, No. 1, pp. 291-305.;;Figueroa, J. M. et al. (2017), Detection of wild-Type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients, Neuro. Oncol., vol. 19, No. 1, pp. 1494-1502.;;Fisher, J. L. et al. (2007), Epidemiology of brain tumors, Neurol. Neurol Clin, vol. 25, pp. 867-890.;;Forbrich, A. et al. (2013), Microbubble-enhanced ultrasound liberation of mRNA biomarkers in vitro, Ultrasound Med. Biol., vol. 39, No. 6, pp. 1087-1093.;;Jadhav, V. et al. (2007), Neuroprotection against Surgically-Induced Brain Injury, Surg Neurol., vol. 67, pp. 15-20.;;Jain K.K (2015), Biomarkers in Neurology, Neurology Medlink, retrieved from https://www.medlink.com/index.php/article/biomarkers_in_neurology#S1 on Sep. 17, 2019, pp. 1-3.;;Jeromin A. et al. (2017), Biomarkers in Neurodegenerative Diseases, Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets, Adv. Neurobiol. vol. 15, pp. 491-528, Springer International Publishing.;;Jones, R. M. et al. (Apr. 16, 2018), Three-dimensional transcranial microbubble imaging for guiding volumetric ultrasound-mediated blood-brain barrier opening, Theranostics vol. 8, No. 11, pp. 2909-2926.;;Kinoshita, M. et al. (2006), Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption, Proc Natl Acad Sci, vol. 103, No. 31, pp. 11719-11723.;;Kothapalli, S. V. V. N. et al. (2017), Acoustic field characterization of a clinical magnetic resonance-guided high-intensity focused ultrasound system inside the magnet bore, Med. Phys., vol. 44, No. 9, pp. 4890-4899.;;Kothapalli, S. V. V. N. et al. (Jul. 2018), A convenient, reliable, and fast acoustic pressure field measurement method for magnetic resonance-guided high-intensity focused ultrasound systems with phased array transducers, J. Ther. Ultrasound, vol. 6, No. 5, pp. 1-8.;;Lun, M. et al. (2011), The natural history of extracranial metastasis from glioblastoma multiforme, J. Neurooncol., vol. 105, No. 2, pp. 261-273.;;Malone, H. et al. (2015), Complications following stereotactic needle biopsy of intracranial tumors, World Neurosurg., vol. 84, No. 4, pp. 1084-1089.;;Martin, E. et al. (2009), High-intensity focused ultrasound for noninvasive functional neurosurgery, Ann. Neurol., vol. 66, No. 6, pp. 858-861.;;Mcdannold, N. et al. (2012), Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques, Cancer Res., vol. 72, No. 14, pp. 3652-3663.;;Merker, J. D. et al. (Oct. 2018), Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review, Arch. Pathol. Lab. Med., vol. 142, No. 10, pp. 1242-1253.;;Miller, A. M. et al. (Jan. 2019), Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid, Nature, vol. 565, No. 7741, pp. 654-658.;;Morel, D. R. et al. (2000), Human pharmacokinetics and safety evaluation of SonoVueTM, a new contrast agent for ultrasound imaging, Invest. Radiol., vol. 35, No. 1, pp. 80-85.;;Mornstein, V. (1997), Cavitation-induced risks associated with contrast agents used in ultrasonography, European Journal of Ultrasound, vol. 5, pp. 101-111.;;Olumolade, O. O. et al. (2016), Longitudinal motor and behavioral assessment of blood-brain barrier opening with transcranial focused ultrasound, Ultrasound Med. Biol., vol. 42, No. 9, pp. 2270-2282.;;Omuro, A. M. P. et al. (2006), Pitfalls in the diagnosis of brain tumours, vol. 5, pp. 937-948.;;Omuro, A. et al. (2013), Glioblastoma and other malignant gliomas: a clinical review, Jama, vol. 310, No. 17, pp. 1842-1850.;;O'Reilly, M. A. et al. (2012), Feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller, Radiology, vol. 263, No. 1, pp. 96-106.;;Paproski, R. J. et al. (2016), Enhanced detection of cancer biomarkers in blood-borne extracellular vesicles using nanodroplets and focused ultrasounc, Cancer Res., vol. 77, No. 1, pp. 3-13.;;Peng, D. et al. (2014), A study of ovarian cancer biomarker amplification using ultrasound for early stage detection, Ultrasonics, vol. 54, pp. 451-454.;;Radovini, N. N. (2015), World first: blood-brain barrier opened non-invasively to deliver chemotherapy, Sunnybrook Health Sciences Centre, Retrieved from https://sunnybrook.ca/media/item.asp?i=1351 on Sep. 22, 2019, pp. 1-2.;;Radovini, N. N. (2017), First Alzheimer's patient treated with focused ultrasound to open the blood-brain barrier, Sunnybrook Health Sciences Centre, Retrieved from https://sunnybrook.ca/media/item.asp?i=1562 on Sep. 22, 2019, pp. 1-3.;;Ragel, B. T. et al. (2015), The role of biopsy in the management of patients with presumed diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline, J. Neurooncol., vol. 125, No. 3, pp. 481-501.;;Schmittgen, T. D., et al. (2008), Analyzing real-time PCR data by the comparative CT method, Nat. Protoc., vol. 3, No. 6, pp. 1101-1108.;;Sirsi, S. et al. (2009), Microbubble compositions, properties, and biomedical applications, Bubble Sci Eng Technol, vol. 1, No. 1-2, pp. 3-17.;;Smith, C. (2017), Biomarkers on the brain: Putting biomarkers together for a better understanding of the nervous system, Science, Special Technology Feature, pp. 1341-1343.;;Staedtke V. et al. (2016), “Actionable Molecular Biomarker: Tumors”, Trends in Cancer, vol. 2, No. 7, pp. 338-349.;;Stride, E. (2009), Physical principles of microbubbles for ultrasound imaging and therapy, Cerebrovasc. Dis., vol. 27, Supp. 2, pp. 1-13.;;Sun, T. et al. (2017), Closed-loop control of targeted ultrasound drug delivery across the blood-brain/tumor barriers in a rat glioma model, Proc. Natl. Acad. Sci., vol. 114, pp. E10281-E10290.;;Taylor, S. C. et al. (2017), Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data, Sci. Rep., vol. 7, No. 2409, pp. 1-8.;;Touat, M et al. (2015), Emerging circulating biomarkers in glioblastoma: promises and challenges, Expert Rev. Mol. Diagn., vol. 15, No. 10, pp. 1311-1323.;;Van Tellingen, O. et al. (2015), Overcoming the blood-brain tumor barrier for effective glioblastoma treatment, Drug Resist. Updat., vol. 19, pp. 1-12.;;Vogel, C. et al. (2012), Insights into the regulation of protein abundance from proteomic and transcriptomic analyses, Nat. Rev. Genet., vol. 13, No. 4, pp. 227-232.;;Warton, K. et al. (2016), Methylated circulating tumor DNA in blood: Power in cancer prognosis and response, Endocrine-Related Cancer, vol. 23, No. 3, pp. R157-R171.;;Westphal, M. et al. (2015), Circulating biomarkers for gliomas, Nat. Publ. Gr., No. 10, pp. 556-566.;;Wood, A. K. W. et al. (2015), A review of low-intensity ultrasound for cancer therapy, Ultrasound Med. Biol., vol. 41, No. 4, pp. 905-928.;;Wu, S.-Y. et al. (2016), Characterizing focused-ultrasound mediated drug delivery to the heterogeneous primate brain in vivo with acoustic monitoring, Sci. Rep., vol. 6, No. 37094, pp. 1-13.;;Wu, S.-Y. et al. (May 2018), Efficient blood-brain barrier opening in primates with neuronavigation-guided ultrasound and real-time acoustic mapping, Sci. Rep., vol. 8, No. 7978, pp. 1-11.;;Yong, E. (2014), Cancer biomarkers: Written in blood, Nature, vol. 511, No. 7511, pp. 524-526.;;Zachariah, M. A. et al. (May 2018), Blood-based biomarkers for the diagnosis and monitoring of gliomas, Neuro. Oncol., vol. 20, No. 9, pp. 1155-1161.;;Zhu, L. et al. (Apr. 26, 2018), Focused ultrasound-enabled brain tumor liquid biopsy, Sci. Rep., vol. 8, No. 6553., pp. 1-9.",ACTIVE
4,US,A1,US 2019/0323086 A1,127-856-676-922-632,2019-10-24,2019,US 201916393322 A,2019-04-24,US 201916393322 A;;US 201862662013 P,2018-04-24,METHODS AND SYSTEMS FOR NONINVASIVE AND LOCALIZED BRAIN LIQUID BIOPSY USING FOCUSED ULTRASOUND,"Among the various aspects of the present disclosure is the provision of a noninvasive and localized brain liquid biopsy using focused ultrasound. Briefly, therefore, the present disclosure is directed to methods and systems to identify brain lesion or tumor characteristics without the need for a solid brain biopsy.",LEUTHARDT ERIC;;DUNN GAVIN;;CHEN HONG;;PETTI ALLEGRA;;UNIV WASHINGTON,LEUTHARDT ERIC;;DUNN GAVIN;;CHEN HONG;;PETTI ALLEGRA,WASHINGTON UNIVERSITY (2019-04-24),https://lens.org/127-856-676-922-632,Patent Application,yes,0,5,3,4,6,A61B10/0045;;A61B2010/0077;;A61B2010/008;;C12Q1/6806;;C12N15/1003;;A61B5/0042;;A61B5/0036;;A61B5/702;;A61B2562/0204;;A61B5/6803;;A61B5/055;;C12Q1/6886;;A61B10/0045;;A61N7/00;;A61B5/055;;A61B5/0042;;A61B5/6803;;C12Q2600/156;;C12Q1/6851;;A61B2010/0077;;A61B2010/008;;A61N2007/006;;A61N2007/0078;;A61N2007/0039;;A61B90/11,C12Q1/6886;;A61B5/00;;A61B5/055;;A61B10/00;;A61B90/11;;A61N7/00;;C12Q1/6851,,0,0,,,,ACTIVE
5,EP,A1,EP 4245384 A1,039-088-551-736-343,2023-09-20,2023,EP 23161922 A,2023-03-14,GB 202203537 A,2022-03-14,FREE-STANDING SPORTS TRAINING WALL,"A free-standing sports training wall is provided, the free-standing sports training wall comprising: a frame; and a substantially smooth heat-strengthened glass panel attached to the frame, the glass panel forming at least part of a rebound surface of the free-standing sports training wall.
",J B CORRIE & CO LTD,DUNN JACK ROBERT;;CHAMBERS DAMIAN GAVIN;;STEVENS BARRY MICHAEL,J.B. CORRIE AND COMPANY LIMITED (2023-09-27),https://lens.org/039-088-551-736-343,Patent Application,yes,7,0,5,5,0,A63B69/0097;;A63B2209/00;;A63B2102/02;;A63B2071/0694;;A63B71/023;;A63C19/08;;A63C2019/085;;A63B69/0097;;A63B63/00;;A63B69/38;;A63B69/0097;;A63B69/38,A63B69/00;;A63B71/02;;A63B71/06;;A63B102/02;;A63C19/08,,0,0,,,,PENDING
6,GB,A,GB 2616621 A,010-182-608-603-516,2023-09-20,2023,GB 202203537 A,2022-03-14,GB 202203537 A,2022-03-14,Free-standing sports training wall,"A free-standing sports training wall comprises a frame 12; and a substantially smooth heat-strengthened glass panel 14 attached to the frame, the glass panel forming at least part of a rebound surface of the free-standing sports training wall. The training wall may be fixedly attached to a sports court, such as a tennis or squash court. The glass panel may include markings 16 which may be formed simultaneously to the heat treatment of the glass panel. The glass panel may be affixed to the frame using attachments 26.",J B CORRIE & COMPANY LTD,JACK ROBERT DUNN;;DAMIAN GAVIN CHAMBERS;;BARRY MICHAEL STEVENS,,https://lens.org/010-182-608-603-516,Patent Application,no,4,0,5,5,0,A63B69/0097;;A63B2209/00;;A63B2102/02;;A63B2071/0694;;A63B71/023;;A63C19/08;;A63C2019/085;;A63B69/0097;;A63B63/00;;A63B69/38;;A63B69/0097;;A63B69/38,A63B69/00;;A63B63/00;;A63B69/38,,0,0,,,,PENDING
7,US,A1,US 2023/0285823 A1,026-159-380-775-295,2023-09-14,2023,US 202318183413 A,2023-03-14,GB 202203537 A,2022-03-14,FREE-STANDING SPORTS TRAINING WALL,"A free-standing sports training wall is provided, the free-standing sports training wall including a frame and a substantially smooth heat-strengthened glass panel attached to the frame. The glass panel forming at least part of a rebound surface of the free-standing sports training wall.",JB CORRIE AND COMPANY LTD,DUNN JACK ROBERT;;CHAMBERS DAMIAN GAVIN;;STEVENS BARRY MICHAEL,JB CORRIE AND COMPANY LIMITED (2023-03-16),https://lens.org/026-159-380-775-295,Patent Application,yes,0,0,5,5,0,A63B69/0097;;A63B2209/00;;A63B2102/02;;A63B2071/0694;;A63B71/023;;A63C19/08;;A63C2019/085;;A63B69/0097;;A63B63/00;;A63B69/38;;A63B69/0097;;A63B69/38,A63B69/00;;A63B69/38,,0,0,,,,PENDING
8,GB,A8,GB 2616621 A8,006-761-317-451-518,2023-10-11,2023,GB 202203537 A,2022-03-14,GB 202203537 A,2022-03-14,Free-standing sports training wall,"A free-standing sports training wall comprises a frame 12; and a substantially smooth heat-strengthened glass panel 14 attached to the frame, the glass panel forming at least part of a rebound surface of the free-standing sports training wall. The training wall may be fixedly attached to a sports court, such as a tennis or squash court. The glass panel may include markings 16 which may be formed simultaneously to the heat treatment of the glass panel. The glass panel may be affixed to the frame using attachments 26.",J B CORRIE AND COMPANY LTD,JACK ROBERT DUNN;;DAMIAN GAVIN CHAMBERS;;BARRY MICHAEL STEVENS,,https://lens.org/006-761-317-451-518,Patent Application,no,0,0,5,5,0,A63B69/0097;;A63B2209/00;;A63B2102/02;;A63B2071/0694;;A63B71/023;;A63C19/08;;A63C2019/085;;A63B69/0097;;A63B63/00;;A63B69/38;;A63B69/0097;;A63B69/38,A63B69/00;;A63B63/00;;A63B69/38,,0,0,,,,PENDING
9,US,A1,US 2023/0287513 A1,166-399-293-749-477,2023-09-14,2023,US 202318156014 A,2023-01-18,US 202318156014 A;;US 201916393322 A;;US 201862662013 P,2018-04-24,METHODS AND SYSTEMS FOR NONINVASIVE AND LOCALIZED BRAIN LIQUID BIOPSY USING FOCUSED ULTRASOUND,"Among the various aspects of the present disclosure is the provision of a noninvasive and localized brain liquid biopsy using focused ultrasound. Briefly, therefore, the present disclosure is directed to methods and systems to identify brain lesion or tumor characteristics without the need for a solid brain biopsy.",WASHINGTON UNIVERSITY ST LOUIS,LEUTHARDT ERIC CLAUDE;;DUNN GAVIN P;;CHEN HONG;;PETTI ALLEGRA,WASHINGTON UNIVERSITY (2019-04-24),https://lens.org/166-399-293-749-477,Patent Application,yes,5,0,3,4,0,A61B10/0045;;A61B2010/0077;;A61B2010/008;;C12Q1/6806;;C12N15/1003;;A61B5/0042;;A61B5/0036;;A61B5/702;;A61B2562/0204;;A61B5/6803;;A61B5/055;;C12Q1/6886;;A61B10/0045;;A61N7/00;;A61B5/055;;A61B5/0042;;A61B5/6803;;C12Q2600/156;;C12Q1/6851;;A61B2010/0077;;A61B2010/008;;A61N2007/006;;A61N2007/0078;;A61N2007/0039;;A61B90/11,C12Q1/6886;;A61B5/00;;A61B5/055;;A61B10/00;;A61B90/11;;A61N7/00;;C12Q1/6851,,0,0,,,,PENDING
10,US,A1,US 2003/0096234 A1,140-227-693-403-358,2003-05-22,2003,US 91190401 A,2001-07-23,US 91190401 A;;US 22005700 P,2000-07-21,Canine toxicity genes,"
   The invention provides for canine genes indicative of toxicological responses to agents such as drugs, pharmaceutical compounds, or chemicals. Methods of identifying and isolating toxicologically relevant canine gene are disclosed. In addition, an array comprising toxicologically relevant canine genes, methods of making a canine gene array, and methods of using a canine gene array in which toxicological responses can analyzed in a rapid and efficient manner are also provided. The methods disclosed herein are also useful for discovering and obtaining novel canine genes. Primers and sequences of novel canine genes are also disclosed. 
",FARR SPENCER B.;;PICKETT GAVIN G.;;NEFT ROBIN EILEEN;;DUNN ROBERT THOMAS,FARR SPENCER B;;PICKETT GAVIN G;;NEFT ROBIN EILEEN;;DUNN ROBERT THOMAS,PHASE-1 MOLECULAR TOXICOLOGY INC (2002-02-18),https://lens.org/140-227-693-403-358,Patent Application,yes,24,2,6,6,0,C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158;;C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158,C07H21/04;;C12N5/06;;C12N9/00;;C12P21/02;;C12Q1/68;;C12Q1/6883,435/6;;435/69.1;;435/183;;X43535;;435/320.1;;536/23.2,0,0,,,,EXPIRED
11,EP,A2,EP 1409718 A2,074-527-923-819-213,2004-04-21,2004,EP 01959161 A,2001-07-23,US 0123311 W;;US 22005700 P,2000-07-21,CANINE TOXICITY GENES,,PHASE 1 MOLECULAR TOXICOLOGY,FARR SPENCER B;;PICKETT GAVIN G;;NEFT ROBIN EILEEN;;DUNN ROBERT THOMAS II,,https://lens.org/074-527-923-819-213,Patent Application,yes,0,0,6,6,0,C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158;;C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158,C07H21/04;;C12N5/06;;C12N9/00;;C12P21/02;;C12Q1/68;;C12Q1/6883,,0,0,,,,DISCONTINUED
12,WO,A3,WO 2002/008453 A3,005-436-038-047-138,2003-08-21,2003,US 0123311 W,2001-07-23,US 22005700 P,2000-07-21,CANINE TOXICITY GENES,"The invention provides for canine genes indicative of toxicological responses to agents such as drugs, pharmaceutical compounds, or chemicals. Methods of identifying and isolating toxicologically relevant canine gene are disclosed. In addition, an array comprising toxicologically relevant canine genes, methods of making a canine gene array, and methods of using a canine gene array in which toxicological responses can analyzed in a rapid and efficient manner are also provided. The methods disclosed herein are also useful for discovering and obtaining novel canine genes. Primers and sequences of novel canine genes are also disclosed.",PHASE 1 MOLECULAR TOXICOLOGY;;FARR SPENCER B;;PICKETT GAVIN G;;NEFT ROBIN EILEEN;;DUNN ROBERT THOMAS II,FARR SPENCER B;;PICKETT GAVIN G;;NEFT ROBIN EILEEN;;DUNN ROBERT THOMAS II,,https://lens.org/005-436-038-047-138,Search Report,yes,5,0,6,6,384,C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158;;C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158,C07H21/04;;C12N5/06;;C12N9/00;;C12P21/02;;C12Q1/68;;C12Q1/6883,,7,7,015-387-320-266-873;;056-723-629-159-475;;033-148-320-518-158;;014-137-729-132-610;;051-542-031-700-795;;014-065-259-226-128;;062-757-709-950-50X,10.1006/abbi.1996.0259;;8660662;;10729191;;10.1006/abbi.2000.1700;;10473073;;10.1093/toxsci/50.1.1;;10445747;;9809554;;10.1038/3282;;8855227;;pmc38202;;10.1073/pnas.93.20.10614;;11099651;;10.1093/toxsci/58.2.399,"KRAEMER STACEY A ET AL: ""Regulation of prostaglandin endoperoxide H synthase-2 expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin."", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 330, no. 2, 1996, pages 319 - 328, XP002236119, ISSN: 0003-9861;;BARTOSIEWICZ MATTHEW ET AL: ""Development of a toxicological gene array and quantitative assessment of this technology."", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 376, no. 1, 1 April 2000 (2000-04-01), pages 66 - 73, XP002236089, ISSN: 0003-9861;;SCHRAML P ET AL: ""Tissue microarrays for gene amplification surveys in many different tumor types."", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES AUG 1999, vol. 5, no. 8, August 1999 (1999-08-01), pages 1966 - 1975, XP001146690, ISSN: 1078-0432;;FARR S ET AL: ""CONCISE REVIEW: GENE EXPRESSION APPLIED TO TOXICOLOGY"", TOXICOLOGICAL SCIENCES, ACADEMIC PRESS, SAN DIEGO, FL, US, vol. 50, no. 1, July 1999 (1999-07-01), pages 1 - 9, XP001096475, ISSN: 1096-6080;;MARTON M J ET AL: ""Drug target validation and identification of secondary drug target effects using DNA microarrays"", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 11, November 1998 (1998-11-01), pages 1293 - 1301, XP002168523, ISSN: 1078-8956;;SCHENA M ET AL: ""PARALLEL HUMAN GENOME ANALYSIS: MICROARRAY-BASED EXPRESSION MONITORING OF 1000 GENES"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 20, 1 October 1996 (1996-10-01), pages 10614 - 10619, XP002022507, ISSN: 0027-8424;;BURCZYNSKI M E ET AL: ""TOXICOGENOMICS-BASED DISCRIMINATION OF TOXIC MECHANISM IN HEPG2 HUMAN HEPATOMA CELLS"", TOXICOLOGICAL SCIENCES, ACADEMIC PRESS, SAN DIEGO, FL,, US, vol. 58, 2000, pages 399 - 415, XP002909258, ISSN: 1096-6080",PENDING
13,US,B2,US 7091033 B2,097-772-921-833-98X,2006-08-15,2006,US 91190401 A,2001-07-23,US 91190401 A;;US 22005700 P,2000-07-21,Array of toxicologically relevant canine genes and uses thereof,"The invention provides for canine genes indicative of toxicological responses to agents such as drugs, pharmaceutical compounds, or chemicals. Methods of identifying and isolating toxicologically relevant canine gene are disclosed. In addition, an array comprising toxicologically relevant canine genes, methods of making a canine gene array, and methods of using a canine gene array in which toxicological responses can analyzed in a rapid and efficient manner are also provided. The methods disclosed herein are also useful for discovering and obtaining novel canine genes. Primers and sequences of novel canine genes are also disclosed.",PHASE 1 MOLECULAR TOXICOLOGY I,FARR SPENCER B;;PICKETT GAVIN G;;NEFT ROBIN EILEEN;;DUNN II ROBERT THOMAS,PHASE-1 MOLECULAR TOXICOLOGY INC (2002-02-18),https://lens.org/097-772-921-833-98X,Granted Patent,yes,33,2,6,6,386,C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158;;C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158,C07H21/04;;C12N5/06;;C12N9/00;;C12P21/02;;C12Q1/68;;C12Q1/6883,435/287.2;;435/6;;435/174;;435/283.1;;435/2;;536/23.1;;536/24.3;;536/24.31,85,47,014-361-481-166-599;;123-488-405-532-075;;024-486-351-916-349;;015-387-320-266-873;;056-723-629-159-475;;033-148-320-518-158;;014-137-729-132-610;;051-542-031-700-795;;014-065-259-226-128;;062-757-709-950-50X;;028-862-168-091-90X;;092-647-544-651-480;;072-482-378-784-721;;023-470-199-156-791;;101-609-764-374-216;;014-822-643-429-54X;;042-522-240-503-590;;106-531-054-438-558;;005-030-354-516-848;;083-740-009-218-722;;087-617-084-673-049;;057-305-689-859-881;;032-728-154-591-070;;075-477-937-707-283;;085-764-009-624-439;;037-148-729-500-127;;017-216-732-209-839;;117-152-927-486-102;;025-944-407-092-767;;015-447-991-049-708;;036-321-603-423-808;;011-746-950-595-993;;018-342-695-508-568;;101-609-764-374-216;;014-822-643-429-54X;;076-801-123-044-407;;106-531-054-438-558;;005-030-354-516-848;;055-581-512-255-298;;054-126-814-549-151;;154-329-972-808-943;;038-657-302-525-132;;025-944-407-092-767;;028-101-983-856-685;;047-864-716-799-879;;069-301-072-482-671;;064-084-044-977-490,12835270;;10.1093/bioinformatics/btg149;;12425984;;10.1006/jtbi.2002.3145;;10.1038/4475;;9915501;;10.1006/abbi.1996.0259;;8660662;;10729191;;10.1006/abbi.2000.1700;;10473073;;10.1093/toxsci/50.1.1;;10445747;;9809554;;10.1038/3282;;8855227;;pmc38202;;10.1073/pnas.93.20.10614;;11099651;;10.1093/toxsci/58.2.399;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1053/jhep.2001.23560;;11343254;;10.1111/j.1749-6632.2000.tb06867.x;;11083097;;10.1186/gb-2001-2-2-research0004;;11182887;;pmc25774;;11103784;;10557283;;pmc23910;;10.1073/pnas.96.23.13118;;pmc113865;;11071945;;10.1093/nar/28.22.4552;;10.1126/science.1354393;;1354393;;8341601;;10.1093/nar/21.14.3269;;pmc309766;;10866209;;10.1038/35015701;;10976071;;10.1126/science.289.5485.1760;;10.1080/08958370050198566;;11114790;;10.1016/0022-2836(70)90057-4;;5420325;;10204799;;10.1002/(sici)1098-2744(199903)24:3<153::aid-mc1>3.0.co;2-p;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10.1093/nar/29.1.152;;11125075;;pmc29818;;10.1016/0196-8858(81)90046-4;;11323195;;10.1016/s0378-4274(01)00267-3;;10.1093/nar/20.19.4965;;pmc334270;;1383934;;6999941;;10.1016/0003-2697(80)90151-7;;10.1038/75603;;10802657;;9276156;;10.1139/cjpp-75-6-731;;10.1139/y97-074;;10632873;;10.1046/j.1365-2958.2000.01730.x;;11103784;;10557283;;pmc23910;;10.1073/pnas.96.23.13118;;10.1101/gr.10.6.789;;pmc310885;;10854411;;10.1126/science.1354393;;1354393;;8341601;;10.1093/nar/21.14.3269;;pmc309766;;10.1007/bf00431247;;1617215;;10700175;;10.1038/73439;;10.1016/s0008-6363(97)00169-7;;9415285;;10.1093/nar/18.24.7213;;2259619;;pmc332855;;10.1093/nar/20.19.4965;;pmc334270;;1383934;;pmc332606;;1979162;;10.1093/nar/18.22.6531;;10.1073/pnas.96.22.12833;;pmc23119;;10536008;;1617217;;10.1007/bf00431249;;10.1006/abio.2000.4846;;11078594,"Ding et al. ""Unsupervised feature selection via two-way ordering in gene expression analysis."" Bioinformatics. vol. 19, No. 10 pp. 1259-1266, 2003.;;Li et al. ""Zipf's law in importance of genes for cancer classification using microarray data."" J. Theor. Bil. vol. 219, pp. 539 551, 2002.;;Debouck et al. ""DNA microarrays in drug discovery and development"" Nature Genetics Supplement. vol. 21, pp. 48-50, Jan. 1999.;;Pirson et al. (Genbank Accession No. X95367, Oct. 1996).;;Yokota (Genbank Accession No. AB008451, Oct. 1997).;;Nakamura et al. (Genbank Accession No. AB012918, Oct. 1999).;;Van Leeuwen et al. (Genbank Accession No. L37107, Feb. 1997).;;Kobayashi et al. (Genbank Accession No. AB028042, Nov. 1999).;;Somberg et al. (Genbank Accession No. U28141, Jun. 1995).;;Kobayashi et al (Genbank Accession No. D84397, Jun. 1999).;;Manning et al. (Genbank Accession No. L31625, Apr. 1994).;;Puel et al. (Genbank Accession No. AF045016, Feb. 1998).;;Ortiz-Garcia et al. (Genbank Accession No. AF021873, Jul. 1999).;;BD Atlas Human cDNA expression array Gene list for cat #7740-1, 1999.;;Kraemer, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, vol. 330, No. 2, Article No. 0259, Academic Press, Inc.;;Bartosiewicz, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, vol. 376, No. 1, Academic Press, Inc.;;Schraml, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, vol. 5, No. 8.;;Farr, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, vol. 50, Society of Toxicology.;;Marton, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, vol. 4, No. 11.;;Schena, et al., Parallel Human Genome Analysis: Microarry-based Expression Monitoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, vol. 93.;;Burczynski, et al., Toxicogenomics-Based Discrimination of Toxic Mechanism in HepG2 Human Hepatoma Cells, Toxicological Sciences, 2000, 399-415, vol. 58, Society of Toxicology.;;U.S. Appl. No. 60/264,933, Farr et al., filed Jan. 29, 2000.;;U.S. Appl. No. 60/220,057, Farr et al., filed Jul. 21, 2000.;;U.S. Appl. No. 60/308,161, Farr et al., filed Jul. 26, 2000.;;U.S. Appl. No. 60/254,232, Farr, filed Dec. 7, 2000.;;Altshul, S. F. et al. (1997). ""Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,"" Nucleic Acids Res. 25(17):3389-3402.;;Amdur, M. O. et al., eds. (1991). Casarett and Doull's Toxicology, 4th edition, Pergamon Press, New York, p. 37. (Includes Table of Contents).;;Bulera, S. J. (2001). ""RNA, Expression in the Early Characterization of the Hepatotoxicants in Wistar Rats by High-Density DNA Microarrays,"" Hepatology 33(5):1239-1258.;;Cortese, J. D. (2000). ""The Array of Today,"" The Scientist 14(17):24-28.;;Cortese, J. D.(2000),. ""Array of Options,"" The Scientist 14(11):25-29.;;Cunningham, M. J. (2000). ""Gene Expression Microarray Data Analysis for Toxicology Profiling,"" Ann. N.Y. Acad. Sci 919:52-67.;;Gennaro, A. R., ed. (1990). Remington's Pharmaceutical Sciences, 18th edition. Mack Publishing Co., Easton, Pennsylvania, pp. xv-xvi (Table of Contents Only).;;Haab, B. B. et al. (2001). ""Protein Microarrays for Highly Parallel Detection and Quantation of Specific Proteins and for Antibodies in Complex Solutions,"" Genome Biol. 2(2):Research 0004.1-0004.13.;;Hayes, A. W., ed (2000). Principles and Methods in Toxicology, Corporate Product Integrity, The Gillette Co., Boston, Massachusetts, pp. v-vii (Table of Contents Only).;;Heuvel, J. P. V., ed. (1997). PCR Protocols in Molecular Toxicology. (Table of Contents only).;;Hough, C.D. et al. (2000). ""Large-Scale Serial Analysis of Gene Expression Reveals Gnes Differentially Expressed in Ovarian Cancer,"" Cancer Res. 60(22):6281-6287.;;http://cmgm.stanford.edu./pbrown.;;http://www.comt.corning.com.;;Johannes, G. et al. (1993). ""Identification of Eukaryotic mRNAs that Are Translated at Reduced Cap Binding Complex elF4F Concentrations Using a cDNA Microarray,"" Proc. Natl. Acad. Sci. 96(23):13118-13123.;;Kane, M. D. et al. (2000). ""Assessment of the Sensitivity and Specificity of Oligonucleotide (50mer), Microarrays,"" Nucleic Acids. Res. 28(22):4552-4557.;;Liang, P. and Pardee (1992). ""Differential Display of Eurkaryotic Messenger RNA by Means of the Polymerase Chain Reaction,"" Science 257:967-971.;;Liang, P. et al. (1993). ""Distribution and Cloning of Eukaryiotic mRNAs by Means of Differential Display: Refinements and Optimization,"" Nucleic Acids Res. 21(14):3269-3275.;;Lockhart, D.J. and Winzeler, E. A. (2000). ""Genomics, Gene Expression and DNA Arrays,"" Nature 405(6788):827-836.;;MacBeath, G. and Schreiber, S. L. (2000). ""Printing Proteins as Microarrays for High-Throughput Function Determination,"" Science 289(5482):1760-1763.;;Nadadur, S.S. et al.(2000). ""A Pulmonary Rat Gene Array for Screening Altered Expression Profiles in Air Pollutant-Induced Lung Injury,"" Inhalation Toxicology 12:1239-1254.;;Needleman, S. B. & Wunsh, C. D. (1970). ""A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,"" J. Mol. Biol. 48:443-451.;;Nuwaysir, E. F. et al. (1999). ""Microarrays and Toxicology: The Advent of Toxicogenomics,"" Molecular Carcinogenesis 24:153-159.;;Pearson, W. R. & Lipman, D. J. (1988). ""Improved Tools for Biological Sequence Comparison,"" Proc. Natal. Acad. Sci. USA. 85:24444.;;Sherlock, G. et al. (2001). ""The Stanford Microarray Database,"" Nucleic Acids Res. 29(1)152-155.;;Smith, T. F. and Waterman, M. S. (1981). ""Comparison of Biosequences,"" Adv. Appl. Math 2:482-489.;;Waring, J. F. et al.(1992). ""Microarray Analysis of Hepatotoxins In Vitro Reveals a Correlation Between Gene Expression Profiles and Mechanisms of Toxicity,"" Toxicol. Lett. 120(1-3):359-368.;;Welsh, J. et al. (1992). ""Arbitrarily Primed PCR Fingerprinting of RNA,"" Nucl. Acids Res. 20(19):4965-4970.;;Ausubel, F. M. et al. eds. (1987). Current Protocols in Molecular Biology. John Wiley & Wiley & Sons, Inc. pp. 1-9. (Table of Contents only).;;Barnes, B. and Gordon, S. (1980). ""Methods for Growth of Cultured Cells in Serum-Free Medium,"" Anal. Biochem. 102:255-270.;;Coligan, J. E. et al, eds (1991). Current Protocols in Immunology, a Wiley & Sons, Inc. Publication. pp. 1-9. (Table of Contents only).;;Diehn, M. et al. (1993). ""Large-Scale Identification of Secreted and Membrane-Associated Gene Products Using DNA Microarrays,"" Nat. Genet. 25:58-62.;;Feuerstein, G. Z., and Wang, X. (1997). ""Use of Differential Display Reverse Transcription-Polymerase Chain Reaction for Discovery of Induced Adrenomedullin Gene Expression in Focal Stoke,"" Can J. Physiol. Pharmacol. 75:731-734.;;Freshney, R. I. ed. (1987). Animal Cell Culture, A Practical Approach. IRL Press, Oxford Washington, DC, pp vii-xii. (Table of Contents only).;;Gait, M. J. ed. (1990). Oligonucleotide Synthesis. IRL Press, Oxford Washington DC, pp vii-xiii. (Table of Contents only).;;Ham, R. G. and Wallace, W. L. (1979). ""Media and Growth Requirements"" In Methods in Enymology vol. LVIII, Academic Press, Inc., pp. 44-93.;;Harlow, E. and Lane, D. (1988). Antibodies: A Laboratory Manual, Harlow, E. and Lane, D. eds., Cold Spring Harbor Laboratory, pp. iii-ix. (Table of Contents only).;;Hayes, A. W. ed. (2000). Principals and Method in Toxicology, Taylor & Frances, pp v-vii. (Table of Contents).;;Hayward, R. E. et al. (1993). ""Shotgun DNA Microarrays and Stage-Specific Gene Expression in Plasmodium falciparum Malaria,"" Mol. Microbiol. 35(1):6-14.;;Heuvel, John P. Vanden, ed. (1997). PCR Protocols in Molecular Toxicology, National Library of Medicine.;;Hough, C. D. et al. (2000). ""Large-Scale Serial Analysis of Gene Expression Reveals Genes Differentially Expressed in Ovarian Canccer,"" Cancer Res. 60:6281-6287.;;Johannes, G. et al. (1999). ""Identification of Eukaryotic mRNAs that Are Translated at Reduced Cap Binding Complex ElF4F Concentrations Using a cDNA Microarray,"" Proc. Nat. Acad. Sci. USA 96(23):13118-13123.;;Klein, P. E. et al. (2000). ""A High-Throughput AFLP-based Method for Constructing Integrated Genetic and Physical Maps: Progress Toward a Sorghum Genome Map,"" Genome Res. 10:789-807.;;Liang, P. and Pardee, A. B. (1992). ""Differential Display of Eurkaryotic Messenger RNA by Means of the Olymerase Chain Reaction"", Science 257:967-971.;;Liang, P. et al. (1993). ""Distribution and Cloning of Eukaryotic mRNAs by Means of Differential Display: Refinements and Optimization,"" Nucl. Acids. Res. 21(14):3269-3275.;;Masseyeff, R. H . et al. eds. (1993). Methods of Immunological Analysis. Weinheim: VCH Verlags gesellschaft mbH, vol. 1-3. (Table of Contents only).;;Miller, J. M. & Carlos, M. P. eds. (1987). Gene Transfer Vectors for Mammalian Cells. Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, pp. vii-ix. (Table of Contents only).;;Mullis, K. B. et al eds. (1994). PCR: The Polymerase Chain Reaction, Birkhäuser Boston, pp xv-xvii. (Table of Contents only).;;Nadeau, J. H. (1992). ""Multilocus Markers for Mouse Genome Analysis: PCR Amplification Based on Single Primers of Arbitrary Nucleotide Sequence,"" Genome 3:55-64.;;Sambrook, J. et al (1989). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, pp xi-xxxviii. (Table of Contents only).;;Scherf, U. et al. (2000). ""A Gene Expression Database for the Molecular Pharmacology of Cancer,"" Nat. Genet. 24:236-44.;;Stahr, H. M. (1991). Analytical Methods in Toxicology. Wiley-Interscience Publication, John Wiley & Sons, Inc. pp. ix-xiii. (Table of Contents Only).;;Wang, X. and Feuerstein, G. Z. (1997). ""The Use of mRNA Differential Display for Discovery of Novel Therapeutic Targets in Cardiovascular Disease,"" Cardiovasc. Res. 35(3):414-421.;;Weir, D. M. & Blackwell, C. C.eds. Handbook of Experimental Immunology in Four Volumes, vol. 1-4. Blackwell Scientific Publication, fourth edition. (Table of Contents only).;;Welsh, J. et al. (1990). ""Fingerprinting Genomes Using PCR with Arbitrary Primers,"" Nucl. Acids Res. 18(24):7213-7218.;;Welsh, J. et al. (1992). ""Arbitrarily Primed PCR Fingerprinting of RNA,"" Nucl. Acid Res. 20:4965-4970.;;Wild, D. ed., (1994). The Immunoassay Handbook, Stockton Press NY, pp i-xix. (Table of Contents only).;;Williams, J. G. K. et al. (1990). ""DNA Polymorphisms Amplified by Arbitrary Primers Are Useful as Genetic Markers,"" Nucl. Acids. Res. 18(22):6531-6535.;;Wilson, M. et al. (1999). ""Exploring Drug-Induced Alterations in Gene Expression in Mycobacterium Tuberculosis by Microarry Hybridization,"" Proc. Nat. Acad. Sci. 96(22):12833-12838.;;Woodward, S. R. et al (1992). ""Random Sequence Olignucleotide Primers Detect polymorphic DNA products which Segregate in Inbred Strains of Mice,"" Genome 3:73-78.;;Ye, S. Q. et al. (2000). ""MiniSage: Gene Expression Profiling Using Serial Analysis of Gene Expression from 1 mug Total RNA,"" Anal. Biochem. 287(1):144-152.",EXPIRED
14,WO,A2,WO 2002/008453 A2,131-627-651-000-610,2002-01-31,2002,US 0123311 W,2001-07-23,US 22005700 P,2000-07-21,CANINE TOXICITY GENES,"The invention provides for canine genes indicative of toxicological responses to agents such as drugs, pharmaceutical compounds, or chemicals. Methods of identifying and isolating toxicologically relevant canine gene are disclosed. In addition, an array comprising toxicologically relevant canine genes, methods of making a canine gene array, and methods of using a canine gene array in which toxicological responses can analyzed in a rapid and efficient manner are also provided. The methods disclosed herein are also useful for discovering and obtaining novel canine genes. Primers and sequences of novel canine genes are also disclosed.",PHASE 1 MOLECULAR TOXICOLOGY;;FARR SPENCER B;;PICKETT GAVIN G;;NEFT ROBIN EILEEN;;DUNN ROBERT THOMAS II,FARR SPENCER B;;PICKETT GAVIN G;;NEFT ROBIN EILEEN;;DUNN ROBERT THOMAS II,,https://lens.org/131-627-651-000-610,Patent Application,yes,0,0,6,6,384,C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158;;C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158,C07H21/04;;C12N5/06;;C12N9/00;;C12P21/02;;C12Q1/68;;C12Q1/6883,,0,0,,,,PENDING
15,AU,A,AU 2001/080746 A,170-417-821-320-457,2002-02-05,2002,AU 2001/080746 A,2001-07-23,US 22005700 P;;US 0123311 W,2000-07-21,Canine toxicity genes,,PHASE 1 MOLECULAR TOXICOLOGY,FARR SPENCER B;;PICKETT GAVIN G;;NEFT ROBIN EILEEN;;DUNN ROBERT THOMAS II,,https://lens.org/170-417-821-320-457,Patent Application,no,0,0,6,6,0,C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158;;C12Q1/68;;C12Q1/6883;;C12Q2600/142;;C12Q2600/158,C07H21/04;;C12N5/06;;C12N9/00;;C12P21/02;;C12Q1/68;;C12Q1/6883,,0,0,,,,PENDING
16,AU,A1,AU 2019/230448 A1,169-056-200-603-36X,2020-10-15,2020,AU 2019/230448 A,2019-03-05,AU 2018/900739 A;;AU 2019/050184 W,2018-03-07,Methods for identifying biological material by microscopy,"The present invention relates generally to the field of computer-based image recognition. More particularly, the invention relates to methods and systems for the identification, and optionally the quantitation of, discrete objects of biological origin such as cells, cytoplasmic structures, parasites, parasite ova, and the like which are typically the subject of microscopic analysis. The invention may be embodied in the form of a method for training a computer to identify a target biological material in a sample. The method may include accessing a plurality of training images, the training images being obtained by light microscopy of one or more samples containing a target biological material and optionally a non-target biological material. The training images are cropped by a human or a computer to produce cropped images, each of which shows predominantly the target biological material. A human then identifies the target biological material in each of the cropped images where identification is possible, and associating an identification label with each of the cropped images where identification was possible. A computer-implemented feature extraction method is then applied to each labelled cropped image. A computer-implemented learning method is then applied to each labelled cropped image to associate extracted features of a biological material with a target biological material.",VERDICT HOLDINGS PTY LTD,CUMMING ALISTAIR;;LAM LUAM;;MCCARTHY CHRISTOPHER;;DUNN MICHELLE;;GAVIN LUKE;;KATTAN SAMAR;;TANG ANTONY,,https://lens.org/169-056-200-603-36X,Patent Application,no,0,0,9,9,0,G06T7/0012;;G06T7/73;;G06T2207/20132;;G06T2207/20021;;G06T2207/20081;;G06T2207/10056;;G06T2207/30004;;G06T2207/20104;;G06V20/695;;G06V20/698;;G16H30/40;;G16H50/20;;G16H10/40;;G06N3/08;;G06N20/10;;G06V20/695;;G06V20/698;;G06V10/945;;G06N3/045;;G16H10/40;;G16B35/00;;G16H30/40;;G16H30/20;;G16H50/20;;G06N3/08;;G06N20/10;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20104;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06N3/045;;G06F18/40;;G06T7/194;;G06T7/11;;G06T7/73;;G16H10/40;;G16H30/40;;G06F16/51;;G06N20/00;;G06T7/0012;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20092;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06F18/2148;;G06F18/40;;G06V10/945,G16H30/00;;G06N5/00;;G06N20/00;;G06T7/00;;G16H30/40,,0,0,,,,PENDING
17,US,A1,US 2021/0056962 A1,050-372-898-505-495,2021-02-25,2021,US 201916544375 A,2019-08-19,US 201916544375 A,2019-08-19,Development of Voice and Other Interaction Applications,"Among other things, a developer of an interaction application for an enterprise can create items of content to be provided to an assistant platform for use in responses to requests of end-users. The developer can deploy the interaction application using defined items of content and an available general interaction model including intents and sample utterances having slots. The developer can deploy the interaction application without requiring the developer to formulate any of the intents, sample utterances, or slots of the general interaction model.",VOICIFY LLC,MCMAHON JEFFREY K;;NAUGHTON ROBERT T;;LAIDLAW NICHOLAS G;;DUNN ALEXANDER M;;BERKOWITZ GAVIN,VOICIFY LLC (2019-08-13),https://lens.org/050-372-898-505-495,Patent Application,yes,0,6,3,14,0,G10L13/033;;G10L13/02;;G06F16/243;;H04M3/4938;;H04M3/493;;H04M2203/355;;H04M2203/305;;G10L15/22;;G06F16/243;;G10L15/1822;;G10L2015/228;;H04M3/4938;;G10L2015/223;;G10L2015/225;;G10L15/1815,G10L15/22;;G06F16/242;;G10L15/18;;H04M3/493,,0,0,,,,ACTIVE
18,US,B2,US 11508365 B2,055-139-402-725-250,2022-11-22,2022,US 201916544375 A,2019-08-19,US 201916544375 A,2019-08-19,Development of voice and other interaction applications,"Among other things, a developer of an interaction application for an enterprise can create items of content to be provided to an assistant platform for use in responses to requests of end-users. The developer can deploy the interaction application using defined items of content and an available general interaction model including intents and sample utterances having slots. The developer can deploy the interaction application without requiring the developer to formulate any of the intents, sample utterances, or slots of the general interaction model.",VOICIFY LLC,MCMAHON JEFFREY K;;NAUGHTON ROBERT T;;LAIDLAW NICHOLAS G;;DUNN ALEXANDER M;;BERKOWITZ GAVIN,,https://lens.org/055-139-402-725-250,Granted Patent,yes,46,1,3,14,0,G10L13/033;;G10L13/02;;G06F16/243;;H04M3/4938;;H04M3/493;;H04M2203/355;;H04M2203/305;;G10L15/22;;G06F16/243;;G10L15/1822;;G10L2015/228;;H04M3/4938;;G10L2015/223;;G10L2015/225;;G10L15/1815,G10L15/22;;G06F16/242;;G10L15/18;;H04M3/493,,20,0,,,"Orbita.ai [online], “Orbita Voice Dialog Editor”, Published on or before Aug. 19, 2019 [retrieved on Aug. 26, 2019], retrieved from URL<https://orbita.ai/orbita-voice-dialog-editor/>, 4 pages.;;Speechmarkdown.org [online], “Simple. Progressive. Cross Platform.”, Published on or before Aug. 19, 2019, [retrieved on Aug. 26, 2019], retrieved from URL <https://www.speechmarkdown.org/> 5 pages.;;Speechmarkdown.org [online], “What Is Speech Markdown?”, Published on or before Aug. 19, 2019, [retrieved on Aug. 26, 2019], retrieved from URL <https://www.speechmarkdown.org/basics/what/> 3 pages.;;Techcrunch.com [online], “Amazon develops a new way to help Alexa answer complex questions”, Jul. 31, 2019 [retrieved on Aug. 26, 2019], retrieved from URL <https://techcrunch.com/2019/07/31/amazon-develops-a-new-way-to-help-alexa-answer-complex-questions/> 6 pages.;;USPTO Transaction History for U.S. Appl. No. 16/544,375, filed Aug. 26, 2019.;;USPTO Transaction History for U.S. Appl. No. 16/544,508, filed Aug. 26, 2019.;;USPTO Transaction History for U.S. Appl. No. 16/544,527, filed Aug. 26, 2019.;;U.S. Appl. No. 16/544,375, filed Aug. 19, 2019—pending.;;U.S. Appl. No. 16/544,508, filed Aug. 19, 2019—pending.;;U.S. Appl. No. 16/544,527, filed Aug. 19, 2019—pending.;;U.S. Appl. No. 16/544,375, filed Aug. 19, 2019—pending, Submitted on Aug. 26, 2019, Submitted on Aug. 26, 2019.;;U.S. Appl. No. 16/544,508, filed Aug. 19, 2019—pending, Olujimi A. Adesanya Gau: 2658, Submitted on Aug. 26, 2019, Submitted on Aug. 26, 2019.;;U.S. Appl. No. 16/544,527, filed Aug. 19, 2019—pending, D. Abebe Gau: 2657, Submitted on Aug. 26, 2019, Submitted on Aug. 26, 2019.;;U.S. Appl. No. 16/544,375, filed Aug. 19, 2019—pending, Submitted on Aug. 10, 2020, Submitted on Aug. 10, 2020.;;U.S. Appl. No. 16/544,508, filed Aug. 19, 2019—issued, Olujimi A. Adesanya Gau: 2658, Submitted on Aug. 10, 2020, Submitted on Aug. 10, 2020.;;U.S. Appl. No. 16/989,807, filed Aug. 10, 2020—pending, Submitted on Aug. 10, 2020, Submitted on Aug. 10, 2020.;;U.S. Appl. No. 16/544,527, filed Aug. 19, 2019—issued, D. Abebe Gau: 2657, Submitted on Aug. 10, 2020, Submitted on Aug. 10, 2020.;;U.S. Appl. No. 16/816,535, filed Mar. 12, 2020—pending, Submitted on Aug. 10, 2020, Submitted on Aug. 10, 2020.;;PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/46201, dated Dec. 29, 2020, 11 pages.;;International Preliminary Report on Patentability in International Application No. PCT/US2020/046201, dated Mar. 3, 2022, 8 pages.",ACTIVE
19,US,B1,US 10614800 B1,075-887-238-071-484,2020-04-07,2020,US 201916544527 A,2019-08-19,US 201916544527 A,2019-08-19,Development of voice and other interaction applications,"Among other things, a developer of an interaction application for an enterprise can create items of content to be provided to an assistant platform for use in responses to requests of end-users. The developer can deploy the interaction application using defined items of content and an available general interaction model including intents and sample utterances having slots. The developer can deploy the interaction application without requiring the developer to formulate any of the intents, sample utterances, or slots of the general interaction model.",VOICIFY LLC,MCMAHON JEFFREY K;;NAUGHTON ROBERT T;;LAIDLAW NICHOLAS G;;DUNN ALEXANDER M;;BERKOWITZ GAVIN,VOICIFY LLC (2019-08-13),https://lens.org/075-887-238-071-484,Granted Patent,yes,16,6,3,14,0,G10L15/22;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/04847;;G06N5/022;;G06N5/04;;G06N5/027;;G06N20/00;;G10L15/1815;;G10L15/22;;G06N20/00;;G06F3/0484;;G06F3/0481,G10L15/00;;G06F3/0481;;G06F3/0484;;G06N20/00;;G10L15/18;;G10L15/22,,10,0,,,"Orbita.ai [online], “Orbita Voice Dialog Editor”, Published on or before Aug. 19, 2019 [retrieved on Aug. 26, 2019], retrieved from URL<https://orbita.ai/orbita-voice-dialog-editor/>, 4 pages.;;Speechmarkdown.org [online], “Simple. Progressive. Cross Platform.”, Published on or before Aug. 19, 2019, [retrieved on Aug. 26, 2019], retrieved from URL<https://www.speechmarkdown.org/> 5 pages.;;Speechmarkdown.org [online], “What Is Speech Markdown?”, Published on or before Aug. 19, 2019, [retrieved on Aug. 26, 2019], retrieved from URL<https://www.speechmarkdown.org/basics/what/> 3 pages.;;Techcrunch.com [online], “Amazon develops a new way to help Alexa answer complex questions”, Jul. 31, 2019 [retrieved on Aug. 26, 2019], retrieved from URL<https://techcrunch.com/2019/07/31/amazon-develops-a-new-way-to-help-alexa-answer-complex-questions/> 6 pages.;;USPTO Transaction History for U.S. Appl. No. 16/544,375 as of Aug. 26, 2019.;;USPTO Transaction History for U.S. Appl. No. 16/544,508 as of Aug. 26, 2019.;;USPTO Transaction History for U.S. Appl. No. 16/544,527 as of Aug. 26, 2019.;;U.S. Appl. No. 16/544,375, filed Aug. 19, 2019—pending.;;U.S. Appl. No. 16/544,508, filed Aug. 19, 2019—pending.;;U.S. Appl. No. 16/544,527, filed Aug. 19, 2019—pending.",ACTIVE
20,KR,A,KR 20200141044 A,158-023-546-333-299,2020-12-17,2020,KR 20207028828 A,2019-03-05,AU 2018/900739 A;;AU 2019/050184 W,2018-03-07,현미경으로 생물학적 물질을 식별하는 방법,"일반적으로 본 발명은 컴퓨터 기반 이미지 인식에 관한 것이다. 보다 상세하게, 본 발명은 일반적으로 현미경 분석의 대상이 되는 세포, 세포질 구조, 기생충, 기생충 난자 및 기타 등등과 같은 생물학적 기원의 개별 객체들의 식별 및 선택적으로는 정량화를 위한 방법 및 시스템에 관한 것이다. 본 발명은 샘플에서 타겟 생물학적 물질을 식별하기 위해 컴퓨터를 트레이닝하는 방법의 형태로 구체화될 수 있다. 상기 방법은, 복수의 트레이닝 이미지들에 액세스하는 단계를 포함하고, 트레이닝 이미지들은 타겟 생물학적 물질 및 선택적으로는 비타겟 생물학적 물질을 포함하는 하나 이상의 샘플들에 대한 광학 현미경 검사에 의해 획득된다. 트레이닝 이미지들은 잘려진 이미지들을 생성하도록 인간 또는 컴퓨터에 의해 잘려지며, 이들 각각은 주로 타겟 생물학적 물질을 보여준다. 인간은 식별이 가능한 잘려진 이미지들 각각에서 타겟 생물학적 물질을 식별하고 식별이 가능했던 하나 이상의 잘려진 이미지들 각각과 식별 라벨을 연관시킨다. 다음으로, 라벨링된 잘려진 이미지들 각각에 컴퓨터 구현 피처 추출 방법이 적용된다. 다음으로, 라벨링된 잘려진 이미지들 각각에 컴퓨터 구현 학습 방법이 적용되어, 생물학적 물질의 하나 이상의 추출된 피처들과 타겟 생물학적 물질을 연관시킨다.",VERDICT HOLDINGS PTY LTD,CUMMING ALISTAIR;;LAM LUAN;;MCCARTHY CHRISTOPHER;;DUNN MICHELLE;;GAVIN LUKE;;KATTAN SAMAR;;TANG ANTONY,,https://lens.org/158-023-546-333-299,Patent Application,no,0,2,9,9,0,G06T7/0012;;G06T7/73;;G06T2207/20132;;G06T2207/20021;;G06T2207/20081;;G06T2207/10056;;G06T2207/30004;;G06T2207/20104;;G06V20/695;;G06V20/698;;G16H30/40;;G16H50/20;;G16H10/40;;G06N3/08;;G06N20/10;;G06V20/695;;G06V20/698;;G06V10/945;;G06N3/045;;G16H10/40;;G16B35/00;;G16H30/40;;G16H30/20;;G16H50/20;;G06N3/08;;G06N20/10;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20104;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06N3/045;;G06F18/40;;G06T7/194;;G06T7/11;;G06T7/73;;G16H10/40;;G16H30/40;;G06F16/51;;G06N20/00;;G06T7/0012;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20092;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06F18/2148;;G06F18/40;;G06V10/945,G16H10/40;;G06K9/00;;G06K9/62;;G06N3/04;;G06N3/08;;G06N20/10;;G16B35/00;;G16H30/20;;G16H30/40,,0,0,,,,PENDING
21,EP,A1,EP 3762934 A1,005-073-301-837-306,2021-01-13,2021,EP 19764633 A,2019-03-05,AU 2018/900739 A;;AU 2019/050184 W,2018-03-07,METHODS FOR IDENTIFYING BIOLOGICAL MATERIAL BY MICROSCOPY,,VERDICT HOLDINGS PTY LTD,CUMMING ALISTAIR;;LAM LUAN;;MCCARTHY CHRISTOPHER;;DUNN MICHELLE;;GAVIN LUKE;;KATTAN SAMAR;;TANG ANTONY,,https://lens.org/005-073-301-837-306,Patent Application,yes,0,0,9,9,0,G06T7/0012;;G06T7/73;;G06T2207/20132;;G06T2207/20021;;G06T2207/20081;;G06T2207/10056;;G06T2207/30004;;G06T2207/20104;;G06V20/695;;G06V20/698;;G16H30/40;;G16H50/20;;G16H10/40;;G06N3/08;;G06N20/10;;G06V20/695;;G06V20/698;;G06V10/945;;G06N3/045;;G16H10/40;;G16B35/00;;G16H30/40;;G16H30/20;;G16H50/20;;G06N3/08;;G06N20/10;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20104;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06N3/045;;G06F18/40;;G06T7/194;;G06T7/11;;G06T7/73;;G16H10/40;;G16H30/40;;G06F16/51;;G06N20/00;;G06T7/0012;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20092;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06F18/2148;;G06F18/40;;G06V10/945,G16H30/00;;G06N5/00;;G06N20/00;;G06T7/00;;G16H30/40,,0,0,,,,PENDING
22,US,B2,US 11538466 B2,130-932-312-762-842,2022-12-27,2022,US 202016816535 A,2020-03-12,US 202016816535 A;;US 201916544527 A,2019-08-19,Development of voice and other interaction applications,"Among other things, a developer of an interaction application for an enterprise can create items of content to be provided to an assistant platform for use in responses to requests of end-users. The developer can deploy the interaction application using defined items of content and an available general interaction model including intents and sample utterances having slots. The developer can deploy the interaction application without requiring the developer to formulate any of the intents, sample utterances, or slots of the general interaction model.",VOICIFY LLC,MCMAHON JEFFREY K;;NAUGHTON ROBERT T;;LAIDLAW NICHOLAS G;;DUNN ALEXANDER M;;BERKOWITZ GAVIN,VOICIFY LLC (2019-08-13),https://lens.org/130-932-312-762-842,Granted Patent,yes,46,1,3,14,0,G10L15/22;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/04847;;G06N5/022;;G06N5/04;;G06N5/027;;G06N20/00;;G10L15/1815;;G10L15/22;;G06N20/00;;G06F3/0484;;G06F3/0481,G10L15/00;;G06F3/0481;;G06F3/0484;;G06N20/00;;G10L15/18;;G10L15/22,,14,0,,,"U.S. Appl. No. 16/544,375, filed Aug. 19, 2019—pending.;;U.S. Appl. No. 16/544,508—issued.;;U.S. Appl. No. 16/989,807—pending.;;U.S. Appl. No. 16/544,527—issued.;;U.S. Appl. No. 16/816,535—pending.;;PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/46201, dated Dec. 29, 2020, 11 pages.;;Orbita.ai [online], “Orbita Voice Dialog Editor”, Published on or before Aug. 19, 2019 [retrieved on Aug. 26, 2019], retrieved from URL<https://orbita.ai/orbita-voice-dialog-editor/>, 4 pages.;;Speechmarkdown.org [online], “Simple. Progressive. Cross Platform.”, Published on or before Aug. 19, 2019, [retrieved on Aug. 26, 2019], retrieved from URL<https://www.speechmarkdown.org/> 5 pages.;;Speechmarkdown.org [online], “What Is Speech Markdown?”, Published on or before Aug. 19, 2019, [retrieved on Aug. 26, 2019], retrieved from URL<https://www.speechmarkdown.org/basics/what/> 3 pages.;;Techcrunch.com [online], “Amazon develops a new way to help Alexa answer complex questions”, Jul. 31, 2019 [retrieved on Aug. 26, 2019], retrieved from URL<https://techcrunch.com/2019/07/31/amazon-develops-a-new-way-to-help-alexa-answer-complex-questions/> 6 pages.;;USPTO Transaction History for U.S. Appl. No. 16/544,375 as of Aug. 26, 2019.;;USPTO Transaction History for U.S. Appl. No. 16/544,508 as of Aug. 26, 2019.;;USPTO Transaction History for U.S. Appl. No. 16/544,527 as of Aug. 26, 2019.;;International Preliminary Report on Patentability in International Application No. PCT/US2020/046201, dated Mar. 3, 2022, 8 pages.",ACTIVE
23,US,A1,US 2021/0248419 A1,030-506-575-712-890,2021-08-12,2021,US 201916978000 A,2019-03-05,AU 2018/900739 A;;AU 2019/050184 W,2018-03-07,METHODS FOR IDENTIFYING BIOLOGICAL MATERIAL BY MICROSCOPY,"The present invention relates generally to the field of computer-based image recognition. More particularly, the invention relates to methods and systems for the identification, and optionally the quantitation of, discrete objects of biological origin such as cells, cytoplasmic structures, parasites, parasite ova, and the like which are typically the subject of microscopic analysis. The invention may be embodied in the form of a method for training a computer to identify a target biological material in a sample. The method may include accessing a plurality of training images, the training images being obtained by light microscopy of one or more samples containing a target biological material and optionally a non-target biological material. The training images are cropped by a human or a computer to produce cropped images, each of which shows predominantly the target biological material. A human then identifies the target biological material in each of the cropped images where identification is possible, and associating an identification label with each of the cropped images where identification was possible. A computer-implemented feature extraction method is then applied to each labelled cropped image. A computer-implemented learning method is then applied to each labelled cropped image to associate extracted features of abiological material with a target biological material.",VERDICT HOLDINGS PTY LTD,CUMMING ALISTAIR;;LAM LUAM;;MCCARTHY CHRISTOPHER;;DUNN MICHELLE;;GAVIN LUKE;;KATTAN SAMAR;;TANG ANTONY,VERDICT HOLDINGS PTY LTD (2021-04-22),https://lens.org/030-506-575-712-890,Patent Application,yes,1,1,9,9,0,G06T7/0012;;G06T7/73;;G06T2207/20132;;G06T2207/20021;;G06T2207/20081;;G06T2207/10056;;G06T2207/30004;;G06T2207/20104;;G06V20/695;;G06V20/698;;G16H30/40;;G16H50/20;;G16H10/40;;G06N3/08;;G06N20/10;;G06V20/695;;G06V20/698;;G06V10/945;;G06N3/045;;G16H10/40;;G16B35/00;;G16H30/40;;G16H30/20;;G16H50/20;;G06N3/08;;G06N20/10;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20104;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06N3/045;;G06F18/40;;G06T7/194;;G06T7/11;;G06T7/73;;G16H10/40;;G16H30/40;;G06F16/51;;G06N20/00;;G06T7/0012;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20092;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06F18/2148;;G06F18/40;;G06V10/945,G06K9/62;;G06F16/51;;G06K9/00;;G06K9/46;;G06T7/00;;G06T7/11;;G06T7/194;;G06T7/73;;G16H10/40;;G16H30/40,,0,0,,,,ACTIVE
24,WO,A1,WO 2019/169432 A1,148-827-655-565-030,2019-09-12,2019,AU 2019/050184 W,2019-03-05,AU 2018/900739 A,2018-03-07,METHODS FOR IDENTIFYING BIOLOGICAL MATERIAL BY MICROSCOPY,"The present invention relates generally to the field of computer-based image recognition. More particularly, the invention relates to methods and systems for the identification, and optionally the quantitation of, discrete objects of biological origin such as cells, cytoplasmic structures, parasites, parasite ova, and the like which are typically the subject of microscopic analysis. The invention may be embodied in the form of a method for training a computer to identify a target biological material in a sample. The method may include accessing a plurality of training images, the training images being obtained by light microscopy of one or more samples containing a target biological material and optionally a non-target biological material. The training images are cropped by a human or a computer to produce cropped images, each of which shows predominantly the target biological material. A human then identifies the target biological material in each of the cropped images where identification is possible, and associating an identification label with each of the cropped images where identification was possible. A computer-implemented feature extraction method is then applied to each labelled cropped image. A computer-implemented learning method is then applied to each labelled cropped image to associate extracted features of a biological material with a target biological material.",VERDICT HOLDINGS PTY LTD,CUMMING ALISTAIR;;LAM LUAM;;MCCARTHY CHRISTOPHER;;DUNN MICHELLE;;GAVIN LUKE;;KATTAN SAMAR;;TANG ANTONY,,https://lens.org/148-827-655-565-030,Patent Application,yes,5,1,9,9,0,G06T7/0012;;G06T7/73;;G06T2207/20132;;G06T2207/20021;;G06T2207/20081;;G06T2207/10056;;G06T2207/30004;;G06T2207/20104;;G06V20/695;;G06V20/698;;G16H30/40;;G16H50/20;;G16H10/40;;G06N3/08;;G06N20/10;;G06V20/695;;G06V20/698;;G06V10/945;;G06N3/045;;G16H10/40;;G16B35/00;;G16H30/40;;G16H30/20;;G16H50/20;;G06N3/08;;G06N20/10;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20104;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06N3/045;;G06F18/40;;G06T7/194;;G06T7/11;;G06T7/73;;G16H10/40;;G16H30/40;;G06F16/51;;G06N20/00;;G06T7/0012;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20092;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06F18/2148;;G06F18/40;;G06V10/945,G16H30/00;;G06N5/00;;G06N20/00;;G06T7/00;;G16H30/40,,0,0,,,,PENDING
25,US,A1,US 2023/0072519 A1,165-226-346-457-143,2023-03-09,2023,US 202217988061 A,2022-11-16,US 202217988061 A;;US 201916544375 A,2019-08-19,Development of Voice and Other Interaction Applications,"Among other things, a developer of an interaction application for an enterprise can create items of content to be provided to an assistant platform for use in responses to requests of end-users. The developer can deploy the interaction application using defined items of content and an available general interaction model including intents and sample utterances having slots. The developer can deploy the interaction application without requiring the developer to formulate any of the intents, sample utterances, or slots of the general interaction model.",VOICIFY LLC,MCMAHON JEFFREY K;;NAUGHTON ROBERT T;;LAIDLAW NICHOLAS G;;DUNN ALEXANDER M;;BERKOWITZ GAVIN,VOICIFY LLC (2019-08-13),https://lens.org/165-226-346-457-143,Patent Application,yes,0,1,3,14,0,G10L13/033;;G10L13/02;;G06F16/243;;H04M3/4938;;H04M3/493;;H04M2203/355;;H04M2203/305;;G10L15/22;;G06F16/243;;G10L15/1822;;G10L2015/228;;H04M3/4938;;G10L2015/223;;G10L2015/225;;G10L15/1815,G10L15/22;;G06F16/242;;G10L15/18;;H04M3/493,,0,0,,,,PENDING
26,CN,A,CN 112204674 A,001-628-547-646-180,2021-01-08,2021,CN 201980030718 A,2019-03-05,AU 2018/900739 A;;AU 2019/050184 W,2018-03-07,METHODS FOR IDENTIFYING BIOLOGICAL MATERIAL BY MICROSCOPY,"The present invention relates generally to the field of computer-based image recognition. More particularly, the invention relates to methods and systems for the identification, and optionally the quantitation of, discrete objects of biological origin such as cells, cytoplasmic structures, parasites, parasite ova, and the like which are typically the subject of microscopic analysis. The inventionmay be embodied in the form of a method for training a computer to identify a target biological material in a sample. The method may include accessing a plurality of training images, the training images being obtained by light microscopy of one or more samples containing a target biological material and optionally a non-target biological material. The training images are cropped by a human or a computer to produce cropped images, each of which shows predominantly the target biological material. A human then identifies the target biological material in each of the cropped images where identification is possible, and associating an identification label with each of the cropped images where identification was possible. A computer-implemented feature extraction method is then applied to each labelled cropped image. A computer-implemented learning method is then applied to each labelled cropped image to associate extracted features of a biological material with a target biological material.",VERDICT HOLDINGS PTY LTD,CUMMING ALISTAIR;;LAM LUAM;;MCCARTHY CHRISTOPHER;;DUNN MICHELLE;;GAVIN LUKE;;KATTAN SAMAR;;TANG ANTONY,,https://lens.org/001-628-547-646-180,Patent Application,no,10,3,9,9,0,G06T7/0012;;G06T7/73;;G06T2207/20132;;G06T2207/20021;;G06T2207/20081;;G06T2207/10056;;G06T2207/30004;;G06T2207/20104;;G06V20/695;;G06V20/698;;G16H30/40;;G16H50/20;;G16H10/40;;G06N3/08;;G06N20/10;;G06V20/695;;G06V20/698;;G06V10/945;;G06N3/045;;G16H10/40;;G16B35/00;;G16H30/40;;G16H30/20;;G16H50/20;;G06N3/08;;G06N20/10;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20104;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06N3/045;;G06F18/40;;G06T7/194;;G06T7/11;;G06T7/73;;G16H10/40;;G16H30/40;;G06F16/51;;G06N20/00;;G06T7/0012;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20092;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06F18/2148;;G06F18/40;;G06V10/945,G16H30/00;;G06N5/00;;G06N20/00;;G06T7/00;;G16H30/40,,0,0,,,,PENDING
27,EP,A4,EP 3762934 A4,045-620-601-150-179,2022-04-06,2022,EP 19764633 A,2019-03-05,AU 2018/900739 A;;AU 2019/050184 W,2018-03-07,METHODS FOR IDENTIFYING BIOLOGICAL MATERIAL BY MICROSCOPY,,VERDICT HOLDINGS PTY LTD,CUMMING ALISTAIR;;LAM LUAN;;MCCARTHY CHRISTOPHER;;DUNN MICHELLE;;GAVIN LUKE;;KATTAN SAMAR;;TANG ANTONY,,https://lens.org/045-620-601-150-179,Search Report,no,1,0,9,9,0,G06T7/0012;;G06T7/73;;G06T2207/20132;;G06T2207/20021;;G06T2207/20081;;G06T2207/10056;;G06T2207/30004;;G06T2207/20104;;G06V20/695;;G06V20/698;;G16H30/40;;G16H50/20;;G16H10/40;;G06N3/08;;G06N20/10;;G06V20/695;;G06V20/698;;G06V10/945;;G06N3/045;;G16H10/40;;G16B35/00;;G16H30/40;;G16H30/20;;G16H50/20;;G06N3/08;;G06N20/10;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20104;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06N3/045;;G06F18/40;;G06T7/194;;G06T7/11;;G06T7/73;;G16H10/40;;G16H30/40;;G06F16/51;;G06N20/00;;G06T7/0012;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20092;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06F18/2148;;G06F18/40;;G06V10/945,G06V20/69;;G06K9/62;;G06N3/04;;G06N3/08;;G06N5/00;;G06N20/00;;G06T7/00;;G16H10/40;;G16H30/00;;G16H30/40;;G16H50/20,,0,0,,,,PENDING
28,US,A1,US 2021/0056959 A1,091-037-526-917-842,2021-02-25,2021,US 202016816535 A,2020-03-12,US 202016816535 A;;US 201916544527 A,2019-08-19,Development of Voice and Other Interaction Applications,"Among other things, a developer of an interaction application for an enterprise can create items of content to be provided to an assistant platform for use in responses to requests of end-users. The developer can deploy the interaction application using defined items of content and an available general interaction model including intents and sample utterances having slots. The developer can deploy the interaction application without requiring the developer to formulate any of the intents, sample utterances, or slots of the general interaction model.",VOICIFY LLC,MCMAHON JEFFREY K;;NAUGHTON ROBERT T;;LAIDLAW NICHOLAS G;;DUNN ALEXANDER M;;BERKOWITZ GAVIN,VOICIFY LLC (2019-08-13),https://lens.org/091-037-526-917-842,Patent Application,yes,0,2,3,14,0,G10L15/22;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/04847;;G06N5/022;;G06N5/04;;G06N5/027;;G06N20/00;;G10L15/1815;;G10L15/22;;G06N20/00;;G06F3/0484;;G06F3/0481,G10L15/18;;G06F3/0481;;G06F3/0484;;G06N20/00;;G10L15/22,,0,0,,,,ACTIVE
29,US,B2,US 11798662 B2,176-714-758-499-827,2023-10-24,2023,US 201916978000 A,2019-03-05,AU 2018/900739 A;;AU 2019/050184 W,2018-03-07,Methods for identifying biological material by microscopy,"The present invention relates generally to the field of computer-based image recognition. More particularly, the invention relates to methods and systems for the identification, and optionally the quantitation of, discrete objects of biological origin such as cells, cytoplasmic structures, parasites, parasite ova, and the like which are typically the subject of microscopic analysis. The invention may be embodied in the form of a method for training a computer to identify a target biological material in a sample. The method may include accessing a plurality of training images, the training images being obtained by light microscopy of one or more samples containing a target biological material and optionally a non-target biological material. The training images are cropped by a human or a computer to produce cropped images, each of which shows predominantly the target biological material. A human then identifies the target biological material in each of the cropped images where identification is possible, and associating an identification label with each of the cropped images where identification was possible. A computer-implemented feature extraction method is then applied to each labelled cropped image. A computer-implemented learning method is then applied to each labelled cropped image to associate extracted features of abiological material with a target biological material.",VERDICT HOLDINGS PTY LTD,CUMMING ALISTAIR;;LAM LUAN DUONG MINH;;MCCARTHY CHRISTOPHER;;DUNN MICHELLE;;GAVIN LUKE;;KATTAN SAMAR;;TANG ANTONY,VERDICT HOLDINGS PTY LTD (2021-04-22),https://lens.org/176-714-758-499-827,Granted Patent,yes,7,0,9,9,0,G06T7/0012;;G06T7/73;;G06T2207/20132;;G06T2207/20021;;G06T2207/20081;;G06T2207/10056;;G06T2207/30004;;G06T2207/20104;;G06V20/695;;G06V20/698;;G16H30/40;;G16H50/20;;G16H10/40;;G06N3/08;;G06N20/10;;G06V20/695;;G06V20/698;;G06V10/945;;G06N3/045;;G16H10/40;;G16B35/00;;G16H30/40;;G16H30/20;;G16H50/20;;G06N3/08;;G06N20/10;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20104;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06N3/045;;G06F18/40;;G06T7/194;;G06T7/11;;G06T7/73;;G16H10/40;;G16H30/40;;G06F16/51;;G06N20/00;;G06T7/0012;;G06T2207/10056;;G06T2207/20021;;G06T2207/20081;;G06T2207/20092;;G06T2207/20132;;G06T2207/30004;;G06V20/695;;G06V20/698;;G06F18/2148;;G06F18/40;;G06V10/945,G06T7/00;;G06F16/51;;G06F18/214;;G06F18/40;;G06N20/00;;G06T7/11;;G06T7/194;;G06T7/73;;G06V10/94;;G06V20/69;;G16H10/40;;G16H30/40,,2,0,,,"International Search Report dated Jun. 14, 2019 for Corresponding International Patent Application PCT/AU2019/050184 Filed on Mar. 5, 2019.;;Written Opinion dated Jun. 14, 2019 For Corres{Ondinginternational Patent Application PCT/AU2019/050184 Filed on Mar. 5, 2019.",ACTIVE
30,AU,A1,AU 2002/323286 A1,038-400-396-954-427,2003-03-03,2003,AU 2002/323286 A,2002-08-16,US 31308001 P;;US 0226514 W,2001-08-16,Human toxicologically relevant genes and arrays,,PHASE 1 MOLECULAR TOXICOLOGY I,NEFT ROBIN E;;SCHMEISER KATJA;;ADKINS KARISSA;;DUNN ROBERT T II;;KIER LARRY D;;ALEN PHILLIPPE;;PICKETT GAVIN G,,https://lens.org/038-400-396-954-427,Patent Application,no,0,0,5,5,0,C12Q1/6883;;C12Q2600/158,C12Q1/68;;C12Q1/6883,,0,0,,,,DISCONTINUED
31,WO,A2,WO 2003/016500 A2,152-357-962-361-952,2003-02-27,2003,US 0226514 W,2002-08-16,US 31308001 P,2001-08-16,HUMAN TOXICOLOGICALLY RELEVANT GENES AND ARRAYS,"The invention provides for a set of toxicologically relevant human genes which may be used to predict toxicological responses on a cellular, organ, or system level. Methods of identifying, selecting, isolating, and evaluating toxicologically relevant human genes are provided. Arrays comprising human genes that are useful for toxicological screening of drugs, pharmaceutical compounds, or chemicals are also provided. The human array provides a method by which toxicological responses can analyzed in a rapid and efficient manner. Methods of identifying and isolating human genes for a human array are also provided. Further, methods of making a human gene array and using a human gene array are disclosed. These methods are also useful for isolating human genes and for discovery of novel human genes. Also provided is a database of human toxicological responses which are useful for predicting toxicological response to agents on a cellular level, organ-by-organ, and system-by-system. Methods of obtaining such databases containing human toxicological data and methods of use are also provided herein. Further, algorithms which allows for evaluation and/or 1 analysis of toxicological data are also provided herein.",PHASE 1 MOLECULAR TOXICOLOGY I;;NEFT ROBIN E;;DUNN ROBERT T II;;ADKINS KARISSA;;PICKETT GAVIN G;;KIER LARRY D;;SCHMEISER KATJA;;ALEN PHILLIPPE,NEFT ROBIN E;;DUNN ROBERT T II;;ADKINS KARISSA;;PICKETT GAVIN G;;KIER LARRY D;;SCHMEISER KATJA;;ALEN PHILLIPPE,,https://lens.org/152-357-962-361-952,Patent Application,yes,0,0,5,5,0,C12Q1/6883;;C12Q2600/158,C12Q1/68;;C12Q1/6883,,0,0,,,,PENDING
32,WO,A3,WO 2003/016500 A3,069-271-345-160-420,2003-06-19,2003,US 0226514 W,2002-08-16,US 31308001 P,2001-08-16,HUMAN TOXICOLOGICALLY RELEVANT GENES AND ARRAYS,"The invention provides for a set of toxicologically relevant human genes which may be used to predict toxicological responses on a cellular, organ, or system level. Methods of identifying, selecting, isolating, and evaluating toxicologically relevant human genes are provided. Arrays comprising human genes that are useful for toxicological screening of drugs, pharmaceutical compounds, or chemicals are also provided. The human array provides a method by which toxicological responses can analyzed in a rapid and efficient manner. Methods of identifying and isolating human genes for a human array are also provided. Further, methods of making a human gene array and using a human gene array are disclosed. These methods are also useful for isolating human genes and for discovery of novel human genes. Also provided is a database of human toxicological responses which are useful for predicting toxicological response to agents on a cellular level, organ-by-organ, and system-by-system. Methods of obtaining such databases containing human toxicological data and methods of use are also provided herein. Further, algorithms which allows for evaluation and/or 1 analysis of toxicological data are also provided herein.",PHASE 1 MOLECULAR TOXICOLOGY I;;NEFT ROBIN E;;DUNN ROBERT T II;;ADKINS KARISSA;;PICKETT GAVIN G;;KIER LARRY D;;SCHMEISER KATJA;;ALEN PHILLIPPE,NEFT ROBIN E;;DUNN ROBERT T II;;ADKINS KARISSA;;PICKETT GAVIN G;;KIER LARRY D;;SCHMEISER KATJA;;ALEN PHILLIPPE,,https://lens.org/069-271-345-160-420,Search Report,yes,2,0,5,5,0,C12Q1/6883;;C12Q2600/158,C12Q1/68;;C12Q1/6883,,1,0,,,See also references of EP 1427850A4,PENDING
33,EP,A2,EP 1427850 A2,067-747-005-329-865,2004-06-16,2004,EP 02757259 A,2002-08-16,US 0226514 W;;US 31308001 P,2001-08-16,HUMAN TOXICOLOGICALLY RELEVANT GENES AND ARRAYS,,PHASE 1 MOLECULAR TOXICOLOGY I,NEFT ROBIN E;;DUNN ROBERT T II;;ADKINS KARISSA;;PICKETT GAVIN G;;KIER LARRY D;;SCHMEISER KATJA;;ALEN PHILLIPPE,,https://lens.org/067-747-005-329-865,Patent Application,yes,0,0,5,5,1919,C12Q1/6883;;C12Q2600/158,C12Q1/68;;C12Q1/6883,,0,0,,,,DISCONTINUED
34,EP,A4,EP 1427850 A4,061-267-066-974-576,2006-02-08,2006,EP 02757259 A,2002-08-16,US 0226514 W;;US 31308001 P,2001-08-16,HUMAN TOXICOLOGICALLY RELEVANT GENES AND ARRAYS,,PHASE 1 MOLECULAR TOXICOLOGY I,NEFT ROBIN E;;DUNN ROBERT T II;;ADKINS KARISSA;;PICKETT GAVIN G;;KIER LARRY D;;SCHMEISER KATJA;;ALEN PHILLIPPE,,https://lens.org/061-267-066-974-576,Search Report,no,4,0,5,5,0,C12Q1/6883;;C12Q2600/158,C12Q1/68;;C12Q1/6883,,1,1,028-308-260-988-56X,11044901;;10.1002/1098-2280(2000)36:3<201::aid-em3>3.0.co;2-1,"YU ZHE ET AL: ""Identification of genes responsive to BPDE treatment in HeLa cells using cDNA expression assays"", ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, vol. 36, no. 3, 2000, pages 201 - 205, XP009054561, ISSN: 0893-6692",DISCONTINUED
